EU

Search documents
X @Forbes
Forbes· 2025-07-09 03:30
Entrepreneurship & Learning - Entrepreneurs gain valuable lessons through trial and error, not in classrooms [1] - Experience, including mistakes and financial losses, is crucial for understanding business [1] Business Strategy - Identifying what truly matters in business is a key outcome of entrepreneurial experience [1]
X @Decrypt
Decrypt· 2025-07-08 23:40
RT GG (@ggDecrypt)Why Ethereum Layer-2 Arbitrum Is Built to Power AAA Games: Offchain Labs CEO► https://t.co/vVC27m6pEl https://t.co/vVC27m6pEl ...
Something STRANGE is going on with Ethereum & Altcoins! (URGENT.)
Altcoin Daily· 2025-07-08 22:47
Eventually, Ethereum will eat the financial world. I believe that the financial system will be rewritten by Ethereum. Something really strange is going on with Ethereum and select altcoins. Pay attention. Over the next 5 minutes, I'll reveal everything to you. Basically, what Wall Street did with Bitcoin in 2023 and 2024, they're about to do with Ethereum and altcoins in 2025 and 2026. Because you know that a major Bitcoin mining company called Bit Digital recently sold 100% of their Bitcoin and are now hol ...
X @The Economist
The Economist· 2025-07-08 21:01
The rise of a property-owning, entrepreneurial middle class in China has transformed its cities this century. But all this has created a new risk: soaring household debt https://t.co/ZILZMOvQjH ...
X @Tesla Owners Silicon Valley
Tesla Owners Silicon Valley· 2025-07-08 20:34
"The vast majority of diseases or brain issues, I think are fixable with a Neuralink device."Elon Muskhttps://t.co/FVCBNaPAV5 ...
Why BitDigital Exited Bitcoin Mining for Ethereum?
Digital Asset News· 2025-07-08 20:28
But this right here is really going to bring it home for Ethereum holders and all pretty much altcoin holders moving forward. So what I'm talking about is there's a great interview and this is the CEO of Bit Digital. This is uh Santaar and he's going to say and it it's it's amazing to me.They had a very successful Bitcoin mining company. They got they stopped all Bitcoin mining. They sold all their Bitcoin.They raised funds for Ethereum. And now they hold over a quarter of a billion dollars in Ethereum. Let ...
Trump’s Truth Social continues crypto push with 'Crypto Blue Chip ETF' filing: CNBC Crypto World
CNBC Television· 2025-07-08 20:22
Today, President Trump's media and technology group files to list a new crypto ETF. Robin Hood CEO Vlad Tennviv defends the company's Open AI and SpaceX stock tokens. And Elliot Chun of Architect Partners discusses the recent wave of crypto M&A activity.Welcome to CNBC's Crypto World. I'm Pelia Kaplan. Crypto prices are mixed along with stocks after President Trump offered no exceptions to his August 1 tariff start date.As of noon Eastern, Bitcoin traded flat, still holding on to the $18,000 level. Aether r ...
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Globenewswire· 2025-07-08 20:10
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2025: 201 ...
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
Globenewswire· 2025-07-08 20:01
Core Insights - Rhythm Pharmaceuticals is set to disclose topline results from a Phase 2 trial evaluating bivamelagon for acquired hypothalamic obesity on July 9, 2025 [1][2] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4] - The company's lead asset, IMCIVREE® (setmelanotide), is approved for treating obesity related to specific genetic conditions [4][5] - Rhythm is advancing a clinical development program for setmelanotide and other investigational MC4R agonists, including bivamelagon and RM-718 [4] Bivamelagon Phase 2 Trial Details - The Phase 2 trial is a randomized, placebo-controlled, double-blind study involving 28 patients aged 12 and older [3] - Patients received daily oral doses of bivamelagon (200 mg, 400 mg, or 600 mg) or placebo for 14 weeks [3] - The primary endpoint is the change in body mass index after 14 weeks of treatment, with an option for patients to continue therapy for up to 52 weeks [3]
X @Ignas | DeFi
Ignas | DeFi· 2025-07-08 19:25
RT mariaa.eth 🐸 (@MariaShen)5/To meet this demand for truly global financial services, a system must be:– Accessible globally (no geographic gatekeeping)– Safe for institutions (security + regulatory clarity)– Resistant to gov't interferenceEthereum delivers all three. https://t.co/z2hNWaejiD ...